-
KNTE Dashboard
- Financials
- Filings
-
Holdings
-
Transcripts
-
ETFs
- Insider
- Institutional
- Shorts
Kinnate Biopharma (KNTE)
Company Profile
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 52.03 mm | 52.03 mm | 52.03 mm | 52.03 mm | 52.03 mm | 52.03 mm |
Cash burn (monthly) | (no burn) | 775.75 k | 11.03 mm | 11.21 mm | 8.51 mm | 8.87 mm |
Cash used (since last report) | n/a | 11.49 mm | 163.42 mm | 166.14 mm | 126.11 mm | 131.40 mm |
Cash remaining | n/a | 40.54 mm | -111.39 mm | -114.11 mm | -74.08 mm | -79.37 mm |
Runway (months of cash) | n/a | 52.3 | -10.1 | -10.2 | -8.7 | -8.9 |
13F holders | Current |
---|---|
Total holders | 61 |
Opened positions | 9 |
Closed positions | 20 |
Increased positions | 15 |
Reduced positions | 21 |
13F shares | Current |
---|---|
Total value | 51.62 bn |
Total shares | 52.69 mm |
Total puts | 1.90 k |
Total calls | 2.50 k |
Total put/call ratio | 0.8 |
Largest owners | Shares | Value |
---|---|---|
Foresite Capital Fund IV | 9.67 mm | $29.98 mm |
Foresite Capital Management IV | 9.67 mm | $13.54 bn |
Orbimed Advisors | 8.01 mm | $11.21 bn |
Foresite Capital Management V | 3.53 mm | $4.94 bn |
Nextech V Oncology S.C.S., SICAV-SIF | 2.33 mm | $0.00 |
Nextech Invest | 2.33 mm | $3.26 bn |
Vida Ventures | 2.21 mm | $0.00 |
Vida Ventures Advisors | 2.21 mm | $3.09 bn |
Lynx1 Capital Management | 2.00 mm | $2.80 bn |
Viking Global Investors | 1.82 mm | $2.55 bn |
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
3 Apr 24 | Gordon Carl L | Common Stock | Sale back to company | Dispose D | Yes | No | 0 | 450,000 | 0.00 | 0 |
3 Apr 24 | Gordon Carl L | Common Stock | Sale back to company | Dispose D | Yes | No | 0 | 84,599 | 0.00 | 0 |
3 Apr 24 | Gordon Carl L | Common Stock | Sale back to company | Dispose D | Yes | No | 0 | 1,368,338 | 0.00 | 0 |
3 Apr 24 | Gordon Carl L | Common Stock | Sale back to company | Dispose D | Yes | No | 0 | 4,738,453 | 0.00 | 0 |
3 Apr 24 | Gordon Carl L | Common Stock | Sale back to company | Dispose D | Yes | No | 0 | 1,368,339 | 0.00 | 0 |
3 Apr 24 | Gordon Carl L | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 3.48 | 25,000 | 87.00 k | 0 |
3 Apr 24 | Gordon Carl L | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 8.38 | 20,250 | 169.70 k | 0 |
3 Apr 24 | Gordon Carl L | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 20 | 40,501 | 810.02 k | 0 |
3 Apr 24 | Sabzevari Helen | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 8.38 | 20,250 | 169.70 k | 0 |
3 Apr 24 | Sabzevari Helen | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 3.48 | 25,000 | 87.00 k | 0 |